Andrew Whitehead

Andrew Whitehead, Vice President, Head of Population Health, leads the global development and execution of strategic integration, inclusive research, and therapeutic areas related to health equity across all functions within the Bristol Myers Squibb (BMS). Andrew’s leadership centers on refining, articulating, and operationalizing the strategic priorities of the BMS health equity strategy. He has successfully embedded this body of work into business imperatives across functions, through assessment of needs and barriers for each priority, and addressing healthcare challenges across Bristol Myers Squibb’s priority disease areas. Andrew has also led his team in addressing global health challenges that include tackling systemic barriers and expanding access to BMS’ medicines and innovations around the world, specifically in low- and middle-income countries. With a keen focus on aligning business objectives with corporate goals, Andrew plays a pivotal role in driving efficiency and effectiveness across BMS. He has also contributed to the development of the organization’s international policy strategy. With nearly 15 years in the biopharma industry, Andrew brings a strong commercial background to Bristol Myers Squibb. Andrew has held numerous strategic and operational positions of increasing responsibility at BMS since he joined the organization in 2011. Prior to assuming his current role leading the Health Equity team, Andrew served as Executive Director, Strategy and Business Operations, Corporate Affairs, where he drove strategic planning, operational excellence, and seamless coordination of initiatives across the Corporate Affairs organization. Andrew was responsible for increasingly strong performance across the entire Hematology portfolio, with a prioritized focus on Multiple Myeloma, and partnered with Academic and Community Oncologists to uncover barriers to treatment and access hurdles for underserved populations. Andrew also built a body of work across the commercial team to drive access to care for MDS, AML, Cell Therapy, NSCLC, HIV, HCV and other therapeutic areas through decisive decision making and resource prioritization.